Skip to main content
SpringerLink
Log in

Baseline characteristics of the Indian cohort from the IMPROVE™ study: a multinational, observational study of biphasic insulin aspart 30 treatment for type 2 diabetes

  • Original Research
  • Published:
Advances in Therapy Aims and scope Submit manuscript

Abstract

Introduction

The IMPROVE™ study is an openlabel, nonrandomized, observational study aimed at determining the safety and efficacy of biphasic insulin aspart 30 (BIAsp 30) treatment in subjects with type 2 diabetes from 11 countries. Here, we report the baseline data of the Indian cohort.

Methods

All subjects with type 2 diabetes requiring insulin and considered suitable for BIAsp 30 therapy based on their physician’s clinical judgment were eligible to enter the study. The data recorded at baseline included demographic characteristics, detailed medical histories, physician-cited reasons for starting BIAsp 30 treatment, and the chosen dosage regimens.

Results

The Indian cohort included 17,995 subjects with diabetes. Poor glycemic control (glycated hemoglobin [HbA1c], 8.7%–9.6%) was observed at baseline in all four geographical zones (North, South, East, and West) and prestudy treatment groups (no therapy, only oral antidiabetic drug [OAD], OAD ± insulin, and OAD ± insulin ± BIAsp 30). Prevalence of both micro- and macrovascular complications was high, also reflecting poor glycemic control. Improving HbA1c and fasting and postprandial blood glucose levels were the most common reasons for starting BIAsp 30 therapy. The subjects were prescribed a mean BIAsp 30 dose of approximately 24 IU, and a twice-daily regimen was employed in almost 80% of subjects.

Conclusion

The baseline results of the IMPROVE study Indian cohort confirm the poor glycemic control and the delayed initiation and/or inadequacy of treatment in subjects with type 2 diabetes. These results also highlight the need for timely and appropriately intensive insulin-based therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Stratton IM, Adler AI, Neil HAW, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000;321:405–412.

    Article  PubMed  CAS  Google Scholar 

  2. Wang PH, Lau J, Chalmers TC. Meta-analysis of effects of intensive blood-glucose control on late complications of type I diabetes. Lancet. 1993;341:1306–1309.

    Article  PubMed  CAS  Google Scholar 

  3. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837–853.

    Article  Google Scholar 

  4. European Diabetes Policy Group. A desktop guide to type 2 diabetes mellitus. Diabet Med. 1999;16:716–730.

    Article  Google Scholar 

  5. Bebakar WMW, Chow CC, Kadir KA, et al. Adding biphasic insulin aspart 30 once or twice daily is more efficacious than optimizing oral antidiabetic treatment in patients with type 2 diabetes. Diabetes Obes Metab. 2007;9:724–732.

    Article  PubMed  CAS  Google Scholar 

  6. Kann PH, Wascher T, Zackova V, et al. Starting insulin therapy in type 2 diabetes: twice-daily biphasic insulin aspart 30 plus metformin versus once-daily insulin glargine plus glimepiride. Exp Clin Endocrinol Diabetes. 2006;114:527–532.

    Article  PubMed  CAS  Google Scholar 

  7. Raskin P, Allen E, Hollander P, et al. Initiating insulin therapy in type 2 diabetes: a comparison of biphasic and basal insulin analogs. Diabetes Care. 2005;28:260–265.

    Article  PubMed  CAS  Google Scholar 

  8. Kilo C, Mezitis N, Jain R, Mersey J, McGill J, Raskin P. Starting patients with type 2 diabetes on insulin therapy using once-daily injections of biphasic insulin aspart 70/30, biphasic human insulin 70/30, or NPH insulin in combination with metformin. J Diabetes Complications. 2003;17:307–313.

    Article  PubMed  Google Scholar 

  9. Yang W, Ji Q, Zhu D, et al. Biphasic insulin aspart 30 three times daily is more effective than a twicedaily regimen without increasing hypoglycemia in Chinese subjects with type 2 diabetes inadequately controlled on oral antidiabetes drugs. Diabetes Care. 2008;31:852–856.

    Article  PubMed  Google Scholar 

  10. Ligthelm RJ, Borzi V, Gumprecht J, Kawamori R, Wenying Y, Valensi P. Importance of observational studies in clinical practice. Clin Ther. 2007;29:1284–1292.

    Article  Google Scholar 

  11. Black N. Why we need observational studies to evaluate the effectiveness of health care. BMJ. 1996;312:1215–1218.

    PubMed  CAS  Google Scholar 

  12. Sharma SK, Joshi SR, Kumar A, et al. Efficacy, safety and acceptability of biphasic insulin aspart 30 in Indian patients with type 2 diabetes: results from the PRESENT study. J Assoc Physicians India. 2008;56:859–863.

    PubMed  CAS  Google Scholar 

  13. Valensi P, Benroubbi M, Borzi V, et al. The IMPROVE T Study — a multinational, observational study in type 2 diabetes: baseline characteristics from eight national cohorts. Int J Clin Pract. 2008:62;1809–1819.

    Article  PubMed  CAS  Google Scholar 

  14. American Diabetes Association. Standards of medical care in diabetes — 2008. Diabetes Care. 2008;31(suppl. 1):S12–S54.

    Article  Google Scholar 

  15. Raheja BS, Kapur A, Bhoraskar A, et al. DiabCare Asia-India Study: diabetes care in India-current status. J Assoc Physicians India. 2001;49:717–722.

    PubMed  CAS  Google Scholar 

  16. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care. 2004;27:1047–1053.

    Article  PubMed  Google Scholar 

  17. Rema M, Premkumar S, Anitha B, Deepa R, Pradeepa R, Mohan V. Prevalence of diabetic retinopathy in urban India: the Chennai Urban Rural Epidemiology Study (CURES) Eye Study-1. Invest Ophthalmol Vis Sci. 2005;46:2328–2333.

    Article  PubMed  Google Scholar 

  18. Pradeepa R, Rema M, Vignesh J, Deepa M, Deepa R, Mohan V. Prevalence and risk factors for diabetic neuropathy in an urban south Indian population: the Chennai Urban Rural Epidemiology Study (CURES-55). Diabet Med. 2008;25:407–412.

    Article  PubMed  CAS  Google Scholar 

  19. Mohan V, Deepa R, Shanthirani CS, Premalatha G. Prevalence of coronary artery disease and its relationship to lipids in a selected population in south India. J Am Coll Cardiol. 2001;38:682–687.

    Article  PubMed  CAS  Google Scholar 

  20. Premalatha G, Shanthirani CS, Deepa R, Markovitz J, Mohan V. Prevalence and risk factors of peripheral vascular disease in a selected south Indian population — the Chennai Urban Population Study (CUPS). Diabetes Care. 2000;23:1295–1300.

    Article  PubMed  CAS  Google Scholar 

  21. Ilkova H, Glaser B, Tunçkale A, Bagriaçik N, Cerasi E. Induction of long-term glycaemic control in newly diagnosed type 2 diabetic patients by transient intensive insulin treatment. Diabetes Care. 1997;20:1353–1356.

    Article  PubMed  CAS  Google Scholar 

  22. Garber AJ, Wahlen J, Wahl T, et al. Attainment of glycaemic goals in type 2 diabetes with once-, twice-, or thrice-daily dosing with biphasic insulin aspart 70/30 (the 1-2-3 study). Diabetes Obes Metab. 2006;8:58–66.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Endocrinology, S. L. Raheja Hospital, Mumbai, India

    Siddharth Shah

  2. JIPMER, Puducherry, India

    A. K. Das

  3. Patna Diabetes Care & Research Centre, Patna, India

    Ajay Kumar

  4. Department of Endocrinology, Amrita Institute of Medical Sciences, Cochin, 682026, Kerala, India

    A. G. Unnikrishnan

  5. Bharti Hospital, Karnal, India

    Sanjay Kalra

  6. Excel Care Hospitals, Guwahati, India

    M. P. Baruah

  7. Department of Endocrinology, St. Johns Hospital, Bangalore, India

    B. Ganapathi

  8. Department of Endocrinology, Osmania Medical College, Hyderabad, India

    R. K. Sahay

Authors
  1. Siddharth Shah
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A. K. Das
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ajay Kumar
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. A. G. Unnikrishnan
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Sanjay Kalra
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. M. P. Baruah
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. B. Ganapathi
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. R. K. Sahay
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to A. G. Unnikrishnan.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Shah, S., Das, A.K., Kumar, A. et al. Baseline characteristics of the Indian cohort from the IMPROVE™ study: a multinational, observational study of biphasic insulin aspart 30 treatment for type 2 diabetes. Adv Therapy 26, 325–335 (2009). https://doi.org/10.1007/s12325-009-0006-9

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12325-009-0006-9

Keywords

Search

Navigation